HIV Infections Clinical Trial
Official title:
Studies of Ocular Complications of AIDS (SOCA)
To monitor trends over time, in the incidence of CMV retinitis and other ocular
complications of AIDS
To determine the effect of highly active anti-retroviral therapy (HAART)-induced immune
status on the risk of developing CMV retinitis and other ocular complications of AIDS
To determine the characteristics (clinical, virologic, hematologic, and biochemical) of a
population at high risk for CMV retinitis and other ocular complications of AIDS
To evaluate the effects of treatments for CMV retinitis and other ocular complications on
visual function, quality of life, and survival.
Ocular abnormalities in patients with AIDS were first reported in 1982. The most common
finding is a non-infectious "HIV retinopathy", characterized by cotton wool spots,
intraretinal hemorrhages, and/or microaneurysms. These changes occur in approximately 50
percent of patients with AIDS. HIV retinopathy alone is not typically associated with
clinical loss of vision, but functional deficits in patients with AIDS without other ocular
complications may be due to this phenomenon.
CMV retinitis has had the most clinical importance of all the associated complications of
AIDS. It is commonly seen in late stage AIDS, and even when treated has the potential to
cause substantial loss of vision. CMV retinitis is also the most costly AIDS-related
opportunistic infection; the mean monthly cost of treatment has been estimated at $7,825.
The incidence of CMV retinitis has varied with changes in the therapeutic and prophylactic
strategies for AIDS and its complications. It has been on the decline in recent years
related to the increased use of highly active anti-retroviral therapy (HAART).
Other ocular complications of AIDS such as ocular toxoplasmosis, herpes zoster retinitis,
and pneumocystis choroidopathy occur less frequently than CMV retinitis and HIV retinopathy.
Their frequency has also changed over the course of the AIDS epidemic.
Because the epidemiology of AIDS is rapidly evolving, with HIV becoming more like a chronic
disease, new information is needed on the incidence and course of ocular complications. We
have little information about the effect of HAART therapy over time on changes in immune
status and the risk of ocular complications of AIDS. More information is also needed to
determine who is at risk for developing ocular complications of AIDS, and how treatment is
affecting their visual function, quality of life, and survival.
The Longitudinal Study of Ocular Complications of AIDS (LSOCA) is prospective observational
study of patients with AIDS. Patients with a prior diagnosis of AIDS according to the 1993
Centers for Disease Control and Prevention (CDC) criteria with or without ocular
complications will be enrolled over a 4 year period. Approximately 2,000 patients will be
enrolled in the study. Enrollment of patients with CMV retinitis at baseline will be between
300 and 600 patients. Followup visits for patients without ocular complications will be
scheduled every 6 months. Followup visits for patients with ocular complications at baseline
or diagnosed during followup will be every 3 months. Followup data will include eye
examinations, fundus photographs, visual function testing, medical history, hematology and
serum chemistry, and collection of plasma and blood cells for banking. Analysis of banked
specimens will include HIV RNA levels and CMV DNA levels.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |